论文部分内容阅读
目的:探讨急性心肌梗死(AMI)并发心源性休克或急性左心衰患者应用BiPAP呼吸机辅助通气后的临床疗效方法: 对18例(?)述患者在常规药物治疗无效时加用BiPAP辅助通气,检测应用前后的血压、心率、呼吸与动脉血气等参数,观察其疗效。结果:18例中死亡2例(11.1%),存活16例(88.9%)。其中经加用BiPAP辅助通气治疗后血压、心率与SaO2等均有明显改善应用12-36h后,上述参数逐步改善直至恢复正常,持续应用时间为4-26d。病情缓解且稳定持续48h以上者可考虑逐步撤除呼吸机。结论:NMI并发心源性休克或急性左心衰在积极药物治疗基础上及早加用BiPAP呼吸机可明显减低死亡率。
Objective: To investigate the clinical efficacy of BiPAP ventilator-assisted ventilation in patients with acute myocardial infarction (AMI) complicated with cardiogenic shock or acute left heart failure: 18 patients (?) Were treated with BiPAP supplemented with routine drug therapy Ventilation, blood pressure before and after testing applications, heart rate, respiration and arterial blood gas and other parameters to observe its efficacy. Results: Of the 18 patients, 2 died (11.1%) and 16 survived (88.9%). The blood pressure, heart rate and SaO2 were significantly improved after the addition of BiPAP-assisted ventilation. After 12-36h of application, the above parameters gradually improved until they returned to normal, and the continuous application time was 4-26 days. Relieved and stable for 48h or more may consider the gradual removal of ventilator. Conclusions: NMI combined with cardiogenic shock or acute left heart failure can reduce mortality significantly by adding BiPAP ventilator on the basis of active drug therapy.